Cybin (HELP) Intangibles (2021 - 2026)
Cybin's (HELP) quarterly Intangibles came in at $30.2 million in Q1 2026, up 5.73% YoY from $28.6 million in Q1 2025, and down 0.71% on a QoQ basis from $30.4 million in Q4 2025.
Cybin (HELP) Intangibles (2021 - 2026) Analysis & Trends
Cybin (HELP) has 6 years of Intangibles data on file, last reported at $30.2 million in Q1 2026.
- Quarterly Intangibles rose 5.73% year-over-year to $30.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.2 million (up 5.73% YoY) and the FY2026 annual result came in at $30.2 million, up 5.93% from the prior year.
- Intangibles slipped to $30.2 million in Q1 2026, from $30.4 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $32.5 million in Q4 2023 to a low of $3.9 million in Q4 2022.
- A 5-year average of $21.7 million and a median of $26.3 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles soared 736.97% — and 2024, when it retreated 19.26%.
- Tracing HELP's Intangibles over 5 years: stood at $3.9 million in 2022, then surged by 736.97% to $32.5 million in 2023, then dropped by 19.26% to $26.2 million in 2024, then increased by 16.0% to $30.4 million in 2025, then declined by 0.71% to $30.2 million in 2026.
- The last three Intangibles figures came in at $30.2 million (Q1 2026), $30.4 million (Q4 2025), and $30.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | 30.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.22 Mn |
| Dec 31, 2025 | 30.44 Mn |
| Sep 30, 2025 | 30.03 Mn |
| Jun 30, 2025 | 30.18 Mn |
| Mar 31, 2025 | 28.59 Mn |
| Dec 31, 2024 | 26.24 Mn |
| Sep 30, 2024 | 26.34 Mn |
| Jun 30, 2024 | 26.12 Mn |
| Mar 31, 2024 | 26.32 Mn |
| Dec 31, 2023 | 32.50 Mn |
| Sep 30, 2023 | 4.31 Mn |
| Jun 30, 2023 | 4.02 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | 3.94 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 1.49 Mn |
| Jun 30, 2021 | 1.42 Mn |
| Mar 31, 2021 | 76,639.61 |